Javier Escaned (head of Section, Interventional Cardiology Unit, Hospital Clinico San Carlos, Madrid, Spain) is a co-course director of EuroPCR (17–20 May, Paris, France). He talks to Cardiovascular News about the highlights of this year’s meeting, discusses the SYNTAX II trial, and explains the influence that the Greek philosopher Aristotle has had on him.
The higher prevalence of depression and anxiety in post-myocardial infarction populations, in comparison with the general population, is well documented.1 Research indicates that individuals and their networks report different effects of, and ways of adjusting to a myocardial infarction—while some adjust well, others experience a sense of shock and ongoing uncertainty regarding their treatment and future health.4,5 Some patients can also have an altered sense of self and experience loss due to a change in their health.6 This commentary reviews the benefits of providing psychological support for patients who experience emotional distress after having a myocardial infarction.
Alfredo R Galassi (University of Catania Italy and University of Zurich, Switzerland) reports on the use of percutaneous coronary intervention (PCI) with the retrograde approach for the management of chronic total occlusions (CTOs) in Europe and how the Euro CTO Club and Live Summit are spreading the knowledge of new complex PCI techniques for CTOs.
Numerous studies have indicated that the transradial approach confers benefit over the transfemoral approach for cardiac catheterisations and percutaneous coronary intervention (PCI).1-4 The latest of these studies, DRAGON, showed that a transradial approach was non-inferior to a transfemoral approach and was associated with a significantly higher rate freedom from bleeding events.5 This commentary explores why the USA, despite the aforementioned data, has been more reluctant than other countries to adopt the transradial approach.
The heart team is at the centre of the success of transcatheter aortic valve implantation (TAVI)—it is involved in patient selection, procedural planning, and post-procedure care. A strong heart team will be of paramount importance for the success of transcatheter mitral valve (TMV) interventions. In this commentary, Vinayak Bapat outlines transcatheter mitral valve interventions and reviews which specialists should comprise the optimal heart team for such procedures.
The first patient has been enrolled in CeloNova BioSciences’ COBRA REDUCE trial, which will study the Cobra PzF nanocoated coronary stent system in patients at a high risk of bleeding. The trial recently received conditional US Food and Drug Administration (FDA) approval.
InEK, the German Institute for the Hospital Renumeration System, has granted the NeoChord DS1000 mitral valve repair system NUB (Neue Untersuchungs- und Behandlungsmethoden) status 1.
The winners of the European Society of Cardiology competitive research programme ‘Grants for Medical Research Innovation’ have been announced. The grants are awarded to research projects that will address areas of unmet medical need in thromboembolic disease.
Francesco Costa (Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands) and others report in Circulation: Cardiovascular Interventions that acute vessel wall injury is common after transradial catheterisation but it is not associated with an increased risk of radial artery occlusion or loss of radial artery pulsation.
Heart attack patients who experience cardiogenic shock have a higher risk of death or rehospitalisation than non-shock patients in the first 60 days post-discharge. By the end of the first year, however, the gap between the two groups narrows, according to a study published today in the Journal of the American College of Cardiology.
The first patient has been enrolled in an investigational device exemption confirmatory study of the second-generation supersaturated oxygen system (SSO2, TherOx) for the improved treatment of acute myocardial infarction (AMI).
The first two patients in the European Peregrine system post-market study have been treated by Wojtek Wojakowski and Mariusz Hochul in Poland, Ablative Solutions has announced.
Boston Scientific and Accenture are to launch a cloud-based, data-driven healthcare system for hospitals. The system, called Advantics Care Pathway Transformation, is designed to help improve patient outcomes and reduce costs to treat patients with chronic cardiovascular diseases.
Admedus has entered into an exclusive distribution agreement with Canadian company Coroneo to sell its Aortic Annuloplasty Ring and a range of specialised surgical instruments for heart valve surgery in Germany and the UK.
Medtronic has announced the recent CE mark receipt and commercial launch for an expanded size matrix of the Resolute Onyx drug-eluting stent (DES), a next generation DES that is now available in 4.5mm and 5mm diameter sizes. The CE mark also approved several new product indications including treatment of left main vessels and small vessels.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos